Menu Search
Equities

Financiere de Tubize SA

TUB:BRU

Financiere de Tubize SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)130.20
  • Today's Change-0.40 / -0.31%
  • Shares traded29.34k
  • 1 Year change+85.73%
  • Beta0.6439
Data delayed at least 15 minutes, as of Sep 18 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Aug-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast

The 2 analysts offering 12 month price targets for Financiere de Tubize SA have a median target of 142.90, with a high estimate of 150.00 and a low estimate of 135.80. The median estimate represents a 9.75% increase from the last price of 130.20.
High15.2%150.00
Med9.8%142.90
Low4.3%135.80

Dividends in EUR

In 2023, Financiere de Tubize SA reported a dividend of 0.68 EUR, which represents a 12.79% increase over last year. The analyst covering the company expects dividends of 1.06 EUR for the upcoming fiscal year, an increase of 56.11%.
Div growth (TTM)12.79%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.